<DOC>
	<DOCNO>NCT00190515</DOCNO>
	<brief_summary>To evaluate clinical effectiveness oral UFT/LV compare 5-FU/l-LV adjuvant therapy stage III colorectal cancer .</brief_summary>
	<brief_title>A Trial Comparing Adjuvant Oral UFT/LV 5-FU/l-LV Stage III Colorectal Cancer ( JCOG-0205-MF )</brief_title>
	<detailed_description>Oral fluoropyrimidines widely use practice postoperative adjuvant chemotherapy curatively resect colorectal cancer Japan . In order evaluate clinical benefit oral anticancer drug adjuvant chemotherapy , conduct randomize controlled trial compare oral combination chemotherapy , UFT+LV , standard intravenous combination chemotherapy , 5-FU+l-LV , stage III colorectal cancer . UFT+LV : UFT 300mg/m2/day LV 75mg/day , orally 28days 7days rest , repeat five time every 5 week . 5-FU+l-LV : 5-FU 500mg/m2 , l-LV 250mg/m2 , weekly administration 6 time , repeat three time every 8 week . Primary endpoint disease-free survival secondary endpoint overall survival adverse event rate .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>1 . Pathologically proved colorectal cancer ( either adenocarcinoma , mucinous carcinoma , signetring cell carcinoma ) . 2 . Tumor mainly locate cecum upper rectum , exclude invades low rectum . 3 . Stage III cancer General Rules Clinical Pathological Studies Cancer Colon , Rectum Anus ( 6th ed . ) , exclude si ( ai ) , n ( ) , M ( ) . 4 . No synchronous colorectal cancer invade muscularis propria deeper . 5 . Tumor resection D2 D3 lymph node dissection perform . 6 . Pathological determination curability tumor resection cur A . 7 . Age registration 20 75 year old . 8 . ECOG Performance status 0 1 . 9 . No prior chemotherapy radiation therapy . 10 . Intake normal diet oral drug possible . 11 . Major organ function preserve . WBC &gt; =3,000/mcl , PLT &gt; =100,000/mcl , GOT &lt; =100 IU/L , GPT &lt; =100 IU/L , T.Bil &lt; =2.0 mg/dl , Cr &lt; =1.5 mg/dl 12 . Adjuvant chemotherapy start within 9 week surgery . 13 . Written inform consent take . 1 . Active coexisting malignancy ï¼ˆsynchronous metachronous malignancy whose disease free period within 5 year ) . Carcinoma situ eligible . 2 . Severe postoperative complication resolve registration . 3 . There follow complication . insulincontrolling uncontrollable diabetes mellitus , uncontrollable hypertension , myocardial infarction within six month unstable angina pectoris , liver cirrhosis , interstitial pneumonia , pulmonary fibrosis , severe emphysema 4 . Pregnant breastfeed woman . 5 . Difficult participate trial , mental disorder psychiatric symptom . 6 . Judged inappropriate register .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>Stage III colorectal cancer</keyword>
	<keyword>5-FU+l-LV</keyword>
	<keyword>UFT+LV</keyword>
	<keyword>randomize control trial</keyword>
</DOC>